U.S. officials acknowledged disagreements over coordinating the international response to the Ebola epidemic in Liberia, but they say most issues are being worked out and the overall fight against the disease there seems to be succeeding.
The names of companies providing lethal injection drugs to the state would be shielded for at least two decades under a bill that cleared the Ohio House on Thursday. Over objections by some Democrats that the proposal goes against government openness and risks more execution-related lawsuits, the Republican-led chamber voted 61-25 in favor of it.
A German federal court has ruled that the liquids contained in e-cigarettes aren't medicinal products and can be sold freely.
Federal health regulators have approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards.
Anthera Pharmaceuticals has signed a manufacturing and supply agreement with the Patheon division of DPx Holdings B.V. The contract provides for Patheon to support the production of the Sollpura clinical drug product for Anthera's Phase III registration trial.
The ECP Series Thermoplastic Quarter Turn Electric Actuators feature a GFPP (Glass Filled Polypropylene) housing that provides the actuator superior corrosion resistance and performance in environments and atmospheres where most metal actuators cannot.
The average cost of developing an approved therapy is around $4.3 billion dollars for companies with three or more approved therapies, according to an analysis completed by Forbes. Imagine, then, our surprise when we discovered a biotechnology company outside of New York City that had developed three approved therapies for an average cost of $0.7 billion dollars – less than 20 percent of the industry average.
The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3B for innovative drugs it helped develop with Vertex Pharmaceuticals. The drug rights were acquired by Royalty Pharma, which owns royalty rights to 40 pharmaceutical medicines.
Vetter has announced the opening of a new representative office in Singapore. The announcement was made at a ceremony attended by members of local government agencies and a number of executives of pharmaceutical/biotech companies with a presence in the Asian region, as well as Vetter executives.
Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.
Study finds significant amount of arsenic in rice products that could have an impact on the health of people who consume it.
A new report by the McKinsey Global Institute says that the global cost of obesity has risen to $2 trillion annually — nearly as much as smoking or the combined impact of armed violence, war and terrorism.
The spread of Ebola remains "intense" in most of Sierra Leone even as things have improved somewhat in the two other countries hardest hit, the World Health Organization says. Some 168 new confirmed cases emerged in a single week in Sierra Leone's capital of Freetown recently, according to a WHO report.
Regeneron Pharmaceuticals and Sanofi have announced that the FDA has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate.
Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.